From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

CLICK HERE FOR CME CREDIT

From a medical cardiologist’s perspective, how do the threshold-setting targets of LDL-C levels of 70 mg/dL apply to PCSK9-based treatment for CV risk reduction? Did the guidelines emphasize sufficiently, the results of the CV outcome trials?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic